A phase II, multicenter, randomized, double-blind, placebo-controlled, ascending, multidose, U.S. study of oral LX1606 (aka LX1032) in patients with refractory symptomatic carcinoid syndrome.
Year: 2011
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: M. Kulke, T. M. O'Dorisio, A. T. Phan, R. M. Langdon, B. J. Marek, N. Iklaque, E. K. Bergsland, J. Freiman, K. Frazier, J. Jackson, B. Zambrowicz
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2589294780